ACCESS and affordability
Access to healthcare
in support to patient organizations in 2022*
invested in research and development in 2022*
*as at end December 2022, source: Annual Report 2022
Increasing knowledge and awareness, and reducing stigma
An important step to increase access to healthcare is to raise disease awareness and reduce potential stigma for those affected. Camurus supports and collaborates with healthcare and patient organizations to increase knowledge about serious and rare diseases. This work is conducted within the framework of the EFPIA (European Federation of Pharmaceutical Industries and Associations) guidelines. For more information on Camurus’ provision of grants and donations to healthcare and patient organizations, see Camurus’ transparency reporting
Camurus conducts activities each year aimed at raising awareness and reducing stigma by supporting international campaigns, such as the Rare Disease Day, Take on Addiction, International Overdose Awareness Day, World Acromegaly Day and World NET Cancer Day. The company also supports initiatives focused on reducing stigma and improving access to treatment for women with opioid dependence – an underrepresented group in treatment programs. For example, in 2023 Camurus supported the campaign “A gateway within all women’s reach”, organized by the non-governmental, not-for-profit organization Dianova International, aimed at reducing stigma and improving women's access and adherence to addiction services.
Throughout the year, Camurus actively participates in leading international medical congresses to exchange knowledge and experiences with the aim of improving access and care for patients.
Developing new innovative medicines for diseases with high unmet medical need
Camurus has a broad and diversified pipeline with product candidates targeting diseases with high unmet medical needs. For some, such as symptomatic polycystic liver disease, there is currently no approved pharmacological treatment available in the EU or US.
In 2022, Camurus invested half a billion SEK in its research and development pipeline to bring forward new innovative treatments for diseases in the focus areas of central nervous system (CNS), rare diseases, oncology and supportive care.
In 2022, Camurus received a request from the Ukrainian Ministry of Health to support Ukrainian patients in need of treatment. After discussions between Camurus and the Ministry, Ukrainian healthcare providers and patient representatives, as well as the World Health Organization (WHO), a decision was made to donate product to Ukraine. After the donation reached Ukraine, Camurus’ medical team conducted training for healthcare professionals in Ukraine in the use of the company’s long-acting treatment.
- Dematteis, M., et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. Dec;18(18):1987-1999, 2017.
- Scott, R., et al. Australian Psychiatry. 2022; 30(4): 498-502